AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 222 min read$PVLA

Goin Kathleen sold $476K of PVLA

Goin Kathleen (Chief Operating Officer) sold 4,302 shares of PALVELLA THERAPEUTICS, INC. (PVLA) at an average of $110.73 ($110.26–$112.23, $0.48M total) across 3 trades on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Goin Kathleen
Published Jun 22, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PVLA
Neutral
medium confidence
Mentioned
$PVLA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PVLANeutralLow
01

Why it matters

The COO’s open-market sale totals ~$476K across three trades at ~$110.26–$112.23/share, executed under a pre-arranged Rule 10b5-1 plan, with holdings reduced to 0 shares.

02

Market read

Traders may monitor PVLA for follow-on insider activity, but this specific disclosure is not a fundamental catalyst.

03

What to watch

The article lacks context on total holdings pre-sale, tax/portfolio needs, and whether other insiders have concurrent activity; these can dominate interpretation.

Relevance 3/10Novelty 3/10Timing: after-hours/filing day (SEC Form 4 filed 2026-06-22)

Background

The article is an SEC Form 4 insider transaction disclosure for Palvella Therapeutics, Inc. (PVLA).

Company-level read

Ticker impact

$PVLANeutralMedium confidence
Context

Palvella Therapeutics COO Goin Kathleen sold 4,302 shares in open-market transactions for about $476K, leaving 0 shares after sale.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and the article provides no new operational/regulatory/financial catalyst.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, a complete exit (0 shares remaining) can still be interpreted by some traders as reduced near-term conviction.

Key entities

  • equity
    PVLA

    Palvella Therapeutics, Inc.; subject of the Form 4 insider sale disclosure.

  • insider
    Goin Kathleen

    Chief Operating Officer who sold 4,302 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PVLA insider trading history →

Related articles

OCT 12
$PVLAMedAI 9/10

Palvella presents data on rapamycin gel, DSAP patient analysis

Palvella Therapeutics (NASDAQ:PVLA) presented data from its Phase 3 SELVA study of QTORIN rapamycin gel, showing 95% of participants improved on the primary endpoint. The company also shared results from a pharmacokinetic substudy and a real-world claims analysis of DSAP patients. Palvella completed its FDA application for QTORIN in August 2026 and plans a Phase 2 trial for QTORIN pitavastatin in Q4 2026.

investing.com2 min
OCT 12
$PVLAMedAI 8/10

An analysis estimates 154,986 U.S. patients were diagnosed with a skin disease over eight years. No FDA-approved treatment exists.

Palvella Therapeutics (Nasdaq: PVLA) presented data at a dermatology conference. Phase 3 SELVA study results showed QTORIN™ rapamycin improved symptoms of microcystic lymphatic malformations (microcystic LMs) with high treatment satisfaction. A real-world claims analysis estimated 154,986 U.S. patients diagnosed with disseminated superficial actinic porokeratosis (DSAP) over eight years.

stocktitan.net2 min
OCT 4
$PVLAMedAI 8/10

Palvella Advances Rare-Disease Drug Toward 2027 Launch

Palvella Therapeutics (PVLA) is preparing for a potential 2027 U.S. launch of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations. The FDA awarded a third year of grant funding for the Phase 3 SELVA trial, and Palvella completed its New Drug Application in August. The company estimates over 30,000 U.S. patients have this rare condition, with no current FDA-approved therapies.

mychesco.com2 min
AUG 31
$PVLAHighAI 9/10

Palvella Completes Rolling NDA For QTORIN Rapamycin In Microcystic Lymphatic Malformatios

Palvella Therapeutics (PVLA) completed its NDA submission to the FDA for QTORIN 3.9% rapamycin anhydrous gel, a potential treatment for microcystic lymphatic malformations (microcystic LMs). The NDA includes Phase 3 SELVA trial results, which met primary and secondary endpoints. The therapy has received Breakthrough Therapy, Fast Track, and Orphan Drug designations. Palvella anticipates a potential commercial launch in early 2027, pending approval.

rttnews.com2 min